Ardelyx (MEX:ARDX) Operating Margin %: -34.71% (As of Mar. 2026)


MEX:ARDX Ardelyx Inc MEX:ARDX
69 GF Score
Price MXN99.00
GF Value MXN195.32
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ardelyx Operating Margin %?

Ardelyx MEX:ARDX 69 Operating Margin % is -34.71% as of Mar. 2026. GuruFocus rates MEX:ARDX with a GF Score™ of 69/100 and a GF Value™ of MXN195.32 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 940 Biotechnology companies, Ardelyx ranks better than 67.45% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Ardelyx's Operating Income for the three months ended in Mar. 2026 was MXN-591 Mil. Ardelyx's Revenue for the three months ended in Mar. 2026 was MXN1,704 Mil. Therefore, Ardelyx's Operating Margin % for the quarter that ended in Mar. 2026 was -34.71%.

Good Sign:

Ardelyx Inc operating margin is expanding. Margin expansion is usually a good sign.

The historical rank and industry rank for Ardelyx's Operating Margin % or its related term are showing as below:

MEX:ARDX' s Operating Margin % Range Over the Past 10 Years
Min: -3488.57   Med: -155.04   Max: -8.38
Current: -8.75


MEX:ARDX's Operating Margin % is ranked better than
67.45% of 940 companies
in the Biotechnology industry
Industry Median: -86.83 vs MEX:ARDX: -8.75

Ardelyx's 5-Year Average Operating Margin % Growth Rate was 68.50% per year.

Ardelyx's Operating Income for the three months ended in Mar. 2026 was MXN-591 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was MXN-685 Mil.


Ardelyx  (MEX:ARDX) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Ardelyx Operating Margin % Related Terms


Ardelyx Operating Margin % Historical Data

* Premium members only.

The historical data trend for Ardelyx's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ardelyx Operating Margin % Chart

Ardelyx Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1,528.63 -122.24 -50.84 -8.38 -10.06

Ardelyx Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.04 -14.74 4.23 4.07 -34.71

MEX:ARDX vs AVLN, INBX, JBIO: Operating Margin % Comparison

For the Biotechnology subindustry, Ardelyx's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ardelyx Operating Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ardelyx's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Ardelyx's Operating Margin % falls into.


MEX:ARDX
69GF Score
Ardelyx Inc MEX:ARDX
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ardelyx Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Ardelyx's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-737.82 / 7334.082
=-10.06 %

Ardelyx's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-591.346 / 1703.603
=-34.71 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -34.71% mean?
Ardelyx (MEX:ARDX) has a Operating Margin % of -34.71% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Ardelyx and its competitors. According to the industry distribution chart, Ardelyx ranks #306 out of 940 companies in the Biotechnology industry, placing it in the top 32.6%.
Is Ardelyx's Operating Margin % too high?
Ardelyx's current Operating Margin % is -34.71%. Based on the distribution chart, Ardelyx ranks #306 out of 940 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Ardelyx has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ardelyx's Operating Margin % compare to AVLN and INBX?
According to the Biotechnology industry distribution chart, Ardelyx ranks #306 out of 940 companies for Operating Margin %. This puts Ardelyx in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Biotechnology company?
A good Operating Margin % depends on the Biotechnology industry context. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Ardelyx and its competitors. Ardelyx's current Operating Margin % is -34.71%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ardelyx stock overvalued right now?
Based on GuruFocus' analysis, Ardelyx (MEX:ARDX) is currently considered Possible Value Trap. The stock's GF Value™ is MXN195.32, compared to a current price of MXN99.00 — trading 49.3% below its estimated fair value. The current Operating Margin % is -34.71%. Ardelyx's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Ardelyx (MEX:ARDX), the current Operating Margin % is -34.71% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ardelyx (MEX:ARDX) Overvalued in 2026?

Based on GuruFocus' analysis, Ardelyx stock appears to be undervalued. The current stock price of MXN99.00 is trading 49.3% below its estimated GF Value™ of MXN195.32. GuruFocus considers Ardelyx to be Possible Value Trap.

Key valuation signals for MEX:ARDX:

  • Operating Margin %: -34.71%
  • GF Value™: MXN195.32 vs. price of MXN99.00 (49.3% below fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the MEX:ARDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ardelyx Business Description

Other Exchanges ARDX:USA41X:Germany
Address 400 Fifth Avenue, Suite 210, Waltham, MA, USA, 02451
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. Its products Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
69GF Score

Get the complete analysis for MEX:ARDX

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN99.00
Price
MXN195.32
GF Value